Item 7.01 Regulation FD Disclosure.

On February 13, 2013, during the Company's previously-announced, publicly available conference call and webcast to discuss fourth quarter and year ended December 31, 2012 financial results, recent developments and detailed findings from the Company's Phase 3 TIVO-1 study in patients with advanced renal cell carcinoma, the Company's Chief Medical Officer, William Slichenmyer, M.D., will make a presentation regarding overall survival and additional data from the TIVO-1 study. A copy of the slides to be used during Dr. Slichenmyer's presentation are attached as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto, which is incorporated by reference herein.

---